Drug Trial Radar · NCT03747653
A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Last checked: Nov 19, 2026Latest source record: May 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
12
Planned (sponsor's estimate)
Start
Mar 8, 2019
Primary completion
May 31, 2020
Study completion May 31, 2020
Sponsor
- Lead sponsor
- Kaifeng Pharmaceutical (Group) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Beijing Furen Biomedical Research Institute Co., Ltd.
- First posted
- Nov 20, 2018
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Male only, from 12 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection at two dose levels in patients with hemophilia A. Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and adverse events in patients with hemophilia A.
Conditions
- Hemophilia A
Interventions
ADVATEDrug
Patients will be administered a single dose of ADVATE.
FRSW107Drug
Patients will be administered a single dose of FRSW107 for Injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum measured concentration of FVIII:C (Cmax).Time frame: Pre-dose and post dose of FRSW107 up to 10 days.
- Time required for the concentration of the drug to reach half of its original value (T1/2).Time frame: Pre-dose and post dose of FRSW107 up to 10 days.
- Area Under the Curve to Infinity (AUC).Time frame: Pre-dose and post dose of FRSW107 up to 10 days.
- The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time (CL).Time frame: Pre-dose and post dose of FRSW107 up to 10 days.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Hematology Department, Beijing Children's Hospital, Capital Medical University
Beijing, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Southern Medical University Nanfang Hospital
Guangzhou, Guangzhou, China
Jinan Central Hospital
Jinan, Shandong, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.